Dan Stanton, Managing editor

August 3, 2020

2 Min Read
MolMed latest add-on for expansion hungry AGC Biologics
Image: iStock/ma-designer491

AGC Biologics has acquired Molecular Medicine (MolMed), increasing its presence in the CDMO space and adding a pipeline of cell and gene therapy candidates.

In March, contract development and manufacturing organization (CDMO) AGC Biologics launched a voluntary tender offer to acquire Italian cell and gene therapy developer and manufacturer MolMed for €240 million ($284 million). Today the deal has been completed, bulking out AGC’s biopharma offering.

On the services side, AGC adds two GMP sites in Milan and Bresso, both in Italy. The former offers 16,000 square-foot of development, testing, and production space and has made over 150 GMP batches of viral vectors and 200 batches of genetically modified cells to support more than 20 clinical trials in Europe and the US.


Image: iStock/ma-designer491

The 35,000 square-foot Bresso site has capacity to produce viral vectors on a 48 L or 200 L scale and genetically modified cells for clinical trials and commercial product.

Both Autolus and Orchard Therapeutics are among MolMed’s customers. Neither firm commented on AGC’s acquisition of their CDMO partner when approached by this publication.

The deal also enters AGC Biologics into the cell and gene therapy end-user space, bringing with it MolMed’s pipeline of autologous and allogeneic CAR therapies.

“We are seeing how clinical trials proceeds, and will look into partnering with pharmaceutical companies,” an AGC Biologics spokesperson told us.

The portfolio includes Zalmoxis, an allogenic T-cell therapy as an add-on therapy to support stem cell transplantation. It was approved in Europe through a conditional marketing authorization in 2016 but subsequently withdrawn by MolMed after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.

The acquisition is the latest add-on by AGC Biologics, the CDMO business of Japanese firm AGC. Having grown the business through acquisitions including Biomeva and CMC Biologics, the firm integrated its CDMO offering in 2018.

Since then, the firm has expanded facilities in Copenhagen, Denmark, and Seattle, Washington, the latest being an $18 million investment at the two sites announced last December. Meanwhile, the CDMO entered the plasmid DNA space  through an expansion at its site in Heidelberg, Germany. And in June, the CDMO paid $100 million to acquire the former AstraZeneca facility in Boulder, Colorado.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like